172 related articles for article (PubMed ID: 28505181)
1. Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions.
Sradhanjali S; Tripathy D; Rath S; Mittal R; Reddy MM
PLoS One; 2017; 12(5):e0177744. PubMed ID: 28505181
[TBL] [Abstract][Full Text] [Related]
2. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
[TBL] [Abstract][Full Text] [Related]
3. Reversal of the Warburg effect with DCA in PDGF‑treated human PASMC is potentiated by pyruvate dehydrogenase kinase‑1 inhibition mediated through blocking Akt/GSK‑3β signalling.
Li B; Zhu Y; Sun Q; Yu C; Chen L; Tian Y; Yan J
Int J Mol Med; 2018 Sep; 42(3):1391-1400. PubMed ID: 29956736
[TBL] [Abstract][Full Text] [Related]
4. PDK1 inhibition is a novel therapeutic target in multiple myeloma.
Fujiwara S; Kawano Y; Yuki H; Okuno Y; Nosaka K; Mitsuya H; Hata H
Br J Cancer; 2013 Jan; 108(1):170-8. PubMed ID: 23321518
[TBL] [Abstract][Full Text] [Related]
5. Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells.
Haugrud AB; Zhuang Y; Coppock JD; Miskimins WK
Breast Cancer Res Treat; 2014 Oct; 147(3):539-50. PubMed ID: 25212175
[TBL] [Abstract][Full Text] [Related]
6. Combination of Taxol® and dichloroacetate results in synergistically inhibitory effects on Taxol-resistant oral cancer cells under hypoxia.
Xie Q; Zhang HF; Guo YZ; Wang PY; Liu ZS; Gao HD; Xie WL
Mol Med Rep; 2015 Apr; 11(4):2935-40. PubMed ID: 25502361
[TBL] [Abstract][Full Text] [Related]
7. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia enhances antitumor activity of dichloroacetate.
Kolesnik DL; Pyaskovskaya ON; Boichuk IV; Solyanik GI
Exp Oncol; 2014 Dec; 36(4):231-5. PubMed ID: 25537215
[TBL] [Abstract][Full Text] [Related]
9. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
10. Multi-modality imaging to assess metabolic response to dichloroacetate treatment in tumor models.
Neveu MA; De Preter G; Joudiou N; Bol A; Brender JR; Saito K; Kishimoto S; Grégoire V; Jordan BF; Krishna MC; Feron O; Gallez B
Oncotarget; 2016 Dec; 7(49):81741-81749. PubMed ID: 28082726
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy.
Pópulo H; Caldas R; Lopes JM; Pardal J; Máximo V; Soares P
Expert Opin Ther Targets; 2015 Jun; 19(6):733-45. PubMed ID: 25976231
[TBL] [Abstract][Full Text] [Related]
12. Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1.
Zhang SL; Yang Z; Hu X; Chakravarty H; Tam KY
Eur J Pharm Sci; 2018 Oct; 123():43-55. PubMed ID: 30012506
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA‑363‑3p inhibits cell proliferation and induces apoptosis in retinoblastoma cells via the Akt/mTOR signaling pathway by targeting PIK3CA.
Ma X; Jin L; Lei X; Tong J; Wang R
Oncol Rep; 2020 May; 43(5):1365-1374. PubMed ID: 32323827
[TBL] [Abstract][Full Text] [Related]
14. Mir-138-5p acts as a tumor suppressor by targeting pyruvate dehydrogenase kinase 1 in human retinoblastoma.
Wang Z; Yao YJ; Zheng F; Guan Z; Zhang L; Dong N; Qin WJ
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(24):5624-5629. PubMed ID: 29271995
[TBL] [Abstract][Full Text] [Related]
15. Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models.
Guo Y; Zhou Y; Wu P; Ran M; Xu N; Shan W; Sha O; Tam KY
Chem Biol Interact; 2023 Jun; 378():110467. PubMed ID: 37004952
[TBL] [Abstract][Full Text] [Related]
16. Antitumor and chemosensitizing action of dichloroacetate implicates modulation of tumor microenvironment: a role of reorganized glucose metabolism, cell survival regulation and macrophage differentiation.
Kumar A; Kant S; Singh SM
Toxicol Appl Pharmacol; 2013 Nov; 273(1):196-208. PubMed ID: 24051182
[TBL] [Abstract][Full Text] [Related]
17. Targeting of two aspects of metabolism in breast cancer treatment.
Gang BP; Dilda PJ; Hogg PJ; Blackburn AC
Cancer Biol Ther; 2014; 15(11):1533-41. PubMed ID: 25482950
[TBL] [Abstract][Full Text] [Related]
18. Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A549 cells.
Shimobaba S; Taga S; Akizuki R; Hichino A; Endo S; Matsunaga T; Watanabe R; Yamaguchi M; Yamazaki Y; Sugatani J; Ikari A
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1170-8. PubMed ID: 26919807
[TBL] [Abstract][Full Text] [Related]
19. Dual-targeting of aberrant glucose metabolism in glioblastoma.
Shen H; Decollogne S; Dilda PJ; Hau E; Chung SA; Luk PP; Hogg PJ; McDonald KL
J Exp Clin Cancer Res; 2015 Feb; 34(1):14. PubMed ID: 25652202
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
